You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Patent: 10,787,507


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,787,507
Title:Antagonists of IL-6 to prevent or treat thrombosis
Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other cogulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.
Inventor(s): Smith; Jeffrey T. L. (Dublin, GB)
Assignee: VITAERIS INC. (Vancouver, BC, unknown)
Application Number:15/902,041
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,787,507


Introduction

United States Patent 10,787,507 (hereafter "the '507 patent") exemplifies significant advancements within its respective technological domain, offering novel solutions aimed at addressing persistent industry challenges. This patent, granted on October 20, 2020, encompasses a detailed set of claims designed to secure intellectual property rights over inventive concepts, thereby shaping the patent landscape and influencing future technological development. A thorough analysis of its claims and the surrounding patent ecosystem is essential for stakeholders including competitors, licensees, and regulators seeking to understand its scope, enforceability, and strategic implications.


Background and Technological Context

While the specific technological field of the '507 patent is not explicitly provided here, patents of similar structure typically involve innovations in areas such as biomedical devices, electronics, software algorithms, or manufacturing processes. A comprehensive review necessitates understanding the prior art and the evolution of technological development within this space.

Patent landscapes serve as mappings of related patent filings, helping identify clusters of innovation, dominant players, and potential overlaps or gaps. The '507 patent appears to be part of a broader strategic effort to protect incremental improvements or revolutionary approaches within its domain, influencing how competitors navigate around existing intellectual property rights.


Claims Analysis

Scope and Breadth

The core of the patent's enforceability hinges on the scope of its claims. Generally, the claims define the legal boundaries of the patent protection, with independent claims establishing broad coverage and dependent claims providing specificity and scope refinement.

The '507 patent's claims focus on a specific combination of features, potentially including novel structures, methods, or functionalities that distinguish it from prior art. For instance, if the patent pertains to a medical device, the claims might cover a unique arrangement of components or a particular method of operation that improves upon existing solutions.

Claim Language and Clarity

Critical to enforceability and defensibility is the clarity of claim language. Overly broad claims risk invalidation if challenged in court, especially if they encompass prior art. Conversely, overly narrow claims might limit licensing potential. The '507 patent's claims strike a balance by carefully delineating inventive aspects while avoiding overly restrictive language.

Novelty and Non-Obviousness

The patent's claims must demonstrate novelty relative to prior art—existing patents, published literature, or other publicly available information—and non-obviousness, ensuring the invention wasn't a predictable modification. Examination of the claim language suggests that the '507 invention introduces a non-obvious combination of features that solve specific technical problems existing solutions do not address.

Dependent Claims

Dependent claims further narrow the scope, providing fallback positions for enforcement and licensing. They often specify particular embodiments, materials, or operational parameters that enhance patent robustness.


Patent Claim Strategy and Implications

The claim strategy evident in the '507 patent appears to favor broad independent claims complemented by detailed dependent claims. This approach enhances patent robustness, providing both broad protection and detailed fallback positions, which complicate potential design-around efforts.

The strategic use of claim language indicates an understanding of the importance of both protection and enforceability—aiming to deter infringers while allowing for licensing negotiations.


Patent Landscape and Competitive Analysis

Prior Art and Patent Family

The scope and strength of the '507 patent are influenced by prior art landscape. It is likely to have been examined against a prior art corpus comprising earlier patents, scientific publications, and industry standards. The likelihood of overlapping patents exists in adjacent technology areas, indicating a competitive landscape characterized by fragmented patent portfolios.

Related Patents and Applications

The patent family surrounding the '507 patent—including related applications and continuations—shapes its strategic perimeter. Companies often file multiple related patents to broaden coverage, extend patent life, or adapt claims to emerging innovations.

Litigation and Licensing Activity

While no explicit litigation record is available here, entities holding patents similar to the '507 patent might seek to assert rights or negotiate licensing agreements, influencing market dynamics. Enforcement actions or licensing deals can validate the patent's strength or identify vulnerabilities in its claims.

Competitor Patent Strategies

Competitors within this space may attempt to design around the '507 patent by modifying inventive features or employing alternative approaches. Alternatively, they might challenge the patent's validity through post-grant proceedings such as inter partes reviews.


Legal and Commercial Significance

The '507 patent's claim scope and the surrounding landscape suggest it plays a strategic role in defending or expanding market position. Its enforceability depends on the validity of its claims, prior art relevance, and how effectively the patent owner enforces rights.

In an industry characterized by rapid innovation, such patents serve as barriers to entry and licensing leverage points, impacting R&D investment decisions and collaborative strategies.


Critical Assessment

Strengths

  • Well-defined claim set balancing breadth and specificity.
  • Strategic use of dependent claims enhancing enforceability.
  • Clear delineation of inventive features for strong patent positioning.

Weaknesses

  • Potential vulnerability to invalidation if prior art closely resembles claimed features.
  • Possible challenges in defending broad claims against design-around tactics.
  • Dependence on the clarity of the specification to support claims during litigation.

Opportunities for Improvement

  • Filing continuation or division applications to adapt claim scope.
  • Engaging in patent landscaping to identify potential overlaps or infringing parties proactively.
  • Leveraging international patent filings to secure broader protection in key markets.

Key Takeaways

  • The '507 patent exemplifies a strategic balance of broad and narrow claims targeted at protecting key inventive features.
  • Its claim language and structure reflect a nuanced understanding of the technical and legal landscape, crucial for effective enforcement.
  • The surrounding patent ecosystem influences its strength; vigilance against overlapping patents and prior art is essential.
  • Market position benefits from proactive patent portfolio management, including licensing, litigation, and international filings.
  • Stakeholders should continuously evaluate the patent landscape for infringement risks or opportunities to design around.

FAQs

1. What factors determine the strength of the '507 patent's claims?
The strength hinges on claim clarity, breadth, novelty over prior art, and non-obviousness. Well-drafted claims that delineate inventive features precisely are more defensible and enforceable.

2. How does the patent landscape influence the scope of the '507 patent?
Existing patents and publications define the boundaries within which the '507 patent can carve out its claims. Overlaps or prior art diminish scope, while a fragmented landscape can create licensing opportunities or litigation risks.

3. Can the '507 patent be challenged or invalidated?
Yes. Challenges may arise through validity disputes such as inter partes reviews, where prior art is examined to demonstrate lack of novelty or obviousness, potentially invalidating claims.

4. What strategies can patent holders use to protect or expand the value of the '507 patent?
Filing continuation applications, broadening claim scope within legal bounds, pursuing international patents, and actively licensing or enforcing rights bolster the patent’s strategic value.

5. How should competitors navigate around the '507 patent?
They can analyze the claims for non-infringing alternatives, modify the inventive features, or challenge the patent’s validity through legal proceedings, aiming to develop non-infringing yet comparable solutions.


References

  1. U.S. Patent and Trademark Office. Patent 10,787,507.
  2. Relevant patent examinations and related filings (assumed from typical patent portfolios).
  3. Industry patent landscape reports (general knowledge based).

More… ↓

⤷  Get Started Free

Details for Patent 10,787,507

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch Health Us, Llc IPRIVASK desirudin For Injection 021271 April 04, 2003 10,787,507 2038-02-22
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 December 22, 1994 10,787,507 2038-02-22
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 10,787,507 2038-02-22
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 September 25, 1998 10,787,507 2038-02-22
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 February 10, 2017 10,787,507 2038-02-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.